ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test
At DNA Labs UAE, we offer the ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test. This genetic test screens for mutations in 200 genes that are associated with an increased risk of developing certain types of cancer.
Test Details
The ONCOPRO HEREDITARY CANCER RISK PANEL is a powerful tool for identifying individuals at an increased risk of developing cancer. The test analyzes DNA samples from a patient’s blood or saliva to detect mutations that may increase their risk of developing cancer. It screens for mutations in genes associated with a wide range of cancers, including breast, ovarian, colorectal, pancreatic, and prostate cancer, among others.
Benefits of the Test
The ONCOPRO HEREDITARY CANCER RISK PANEL allows for earlier detection of cancer and potentially life-saving interventions. By identifying individuals who may have an inherited predisposition to cancer, personalized prevention and treatment strategies can be developed. The test can also inform cancer treatment decisions, as certain genetic mutations may affect how a patient responds to certain therapies.
Test Cost
The cost of the ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test is AED 6740.0.
Symptoms and Diagnosis
Individuals who may benefit from this test include those with a personal or family history of cancer, as well as those who have certain genetic syndromes that increase their risk of developing cancer. If you experience any symptoms associated with cancer or have concerns about your risk, it is important to consult with an oncologist for further evaluation and guidance.
Sample Collection and Delivery
A 10 mL (8 mL min.) whole blood sample is required for the test. The sample should be collected in 1 Lavender Top (EDTA) tube and shipped immediately at 18-22°C. It is important not to refrigerate or freeze the sample. The test results will be delivered within 35 working days.
Pre-Test Information
Before undergoing the ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test, it is mandatory to fill out the Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27).
Method and Test Type
The ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test is performed using Next Generation Sequencing. It falls under the category of molecular diagnostics and is specifically designed to detect cancer-related genetic mutations.
Conclusion
The ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test offered by DNA Labs UAE is a comprehensive and advanced genetic test that can identify individuals at an increased risk of developing cancer. By providing early detection and personalized treatment strategies, this test can play a crucial role in saving lives and improving patient outcomes.
| Test Name | ONCOPRO HEREDITARY CANCER RISK PANEL Screens 200 Genes Test |
|---|---|
| Components | AIP CBL CYLD EXT2 GNAII MEN1 NTRK2 PTPN11 SAMD9L STAT3 ALK CD70 DDB2 EZH2 GPC3 MET NTRK3 PTPN13 SBDS STK11 ANKRD26 CD82 DDX41 FAM111B GPR101 MITF PALB2 RAD50 SDHA SUFU AP2S1 CDC73 DICER1 FAM175A GREM1 MLH1 PALLD RAD51C SDHAF2 TERT APC CDH1 DIS3L2 FANCA HNF1A MLH3 PAX5 RAD51D SDHB TGFBR2 APOBEC3B CDH10 DKC1 FANCB HNF1B MPL PDGFRA RAF1 SDHC TINF2 AR CDK4 EFNA1 FANCC HOXB13 MRE11A PHOX2B RASA2 SDHD TMEM127 ATM CDKN1A EGFR FANCD2 HRAS MSH2 PMS1 RB1 SETBP1 TP53 ATR CDKN1B ELAC2 FANCE IKZF1 MSH3 PMS2 RECQL SHOC2 TP63 AXIN2 CDKN1C ELANE FANCF KDR MSH6 POLD1 RECQL4 SLX4 TSC1 BAP1 CDKN2A ENG FANCG KIF1B MSR1 POLE REST SMAD4 TSC2 BARD1 CDKN2B EPCAM FANCI KIT MUTYH POLH RET SMARCA4 VHL BLM CDKN2C ERCC1 FANCL KITLG NBN POLQ RHBDF2 SMARCB1 WRN BMPR1A CEBPA ERCC2 FANCM KRAS NF1 POT1 RIT1 SMARCE1 WT1 BRAF CEP57 ERCC3 FEN1 LMO1 NF2 PPM1D RNASEL SOS1 XPA BRCA1 CFTR ERCC4 FH LZTR1 NRAS PRF1 RNF43 SOS2 XPC BRCA2 CHEK2 ERCC5 FLCN MAP2K1 NSD1 PRKAR1A RPS20 SPINK1 XRCC2 BRIP1 CRTAC1 ETV6 GALNT12 MAP2K2 NSUN2 PRSS1 RRAS SPOP XRCC3 BUB1B CTNNA1 EXO1 GATA2 MAX NTHL1 PTCH1 RUNX1 SPRED1 CD82 CASR CTRC EXT1 GCM2 MC1R NTRK1 PTEN SAMD9 SRP72 MXI1 |
| Price | 6740.0 AED |
| Sample Condition | 10 mL (8 mL min.) whole bloodin 1 Lavender Top (EDTA) tube. Ship immediately at 18\u0192??22?\u00f8C. DO NOT REFRIGERATE OR FREEZE. Duly filled Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) is mandatory. |
| Report Delivery | Sample Daily by 9 am; Report 35 Working days |
| Method | Next Generation Sequencing |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | Duly filled Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) is mandatory. |
| Test Details | The Oncopro Hereditary Cancer Risk Panel is a genetic test that screens for mutations in 200 genes that are associated with an increased risk of developing certain types of cancer. The test is designed to identify individuals who may have an inherited predisposition to cancer, allowing for earlier detection and potentially life-saving interventions. The panel includes genes associated with a wide range of cancers, including breast, ovarian, colorectal, pancreatic, and prostate cancer, among others. The test analyzes DNA samples from a patient’s blood or saliva to detect mutations that may increase their risk of developing cancer. The Oncopro Hereditary Cancer Risk Panel is typically recommended for individuals with a personal or family history of cancer, as well as those who have certain genetic syndromes that increase their risk of developing cancer. The test can also be used to inform cancer treatment decisions, as certain genetic mutations may affect how a patient responds to certain therapies. Overall, the Oncopro Hereditary Cancer Risk Panel is a powerful tool for identifying individuals at increased risk of developing cancer and guiding personalized cancer prevention and treatment strategies. |
